Page last updated: 2024-11-12

5'-deoxy-5-fluorocytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5'-deoxy-5-fluorocytidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10037499
CHEMBL ID3244492
CHEBI ID80627
SCHEMBL ID331944
MeSH IDM0376516

Synonyms (25)

Synonym
AC-4244
66335-38-4
AKOS015840076
5'-deoxy-5-fluorocytidine
5'-dfcr
cytidine, 5'-deoxy-5-fluoro-
4-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidin-2(1h)-one
8rwb05i6on ,
unii-8rwb05i6on
cytidine, 5'-deoxy-5-fluoro
AKOS015896907
5'-deoxy-5-fluoro cytidine
CHEMBL3244492
SCHEMBL331944
CHEBI:80627 ,
YSNABXSEHNLERR-ZIYNGMLESA-N
DTXSID00216543
5`-deoxy-5-fluorocytidine
4-amino-1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoropyrimidin-2(1h)-one (5'-deoxy-5-fluorocytidine)
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidin-2-one
Q27149675
AS-15620
EN300-396607
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-1,2-dihydropyrimidin-2-one
PD053791

Research Excerpts

Pharmacokinetics

The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites. The study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5'-deoxy-5-fluorouridine (5'-DFUR), 5-FU and fluoro-β-alanine.

ExcerptReferenceRelevance
"Nine patients treated with CCB and BVZ for advanced colorectal cancer entered this pharmacokinetic study."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" After repeated cycles of BVZ no significant pharmacokinetic interaction was observed."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
"From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (dFCR), 5'-deoxy-5-fluorouridine (dFUR), 5-FU, and fluoro-β-alanine (FBAL) using data from a heterogeneous population of cancer patients (n = 237) who participated in seven clinical studies."( Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM, 2019
)
0.73
" This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5'-deoxy-5-fluorouridine (5'-DFUR) from 5'-deoxy-5-fluorocytidine (5'-DFCR), as well as creatinine clearance (CLcr)."( Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
Ando, Y; Fujita, KI; Hattori, N; Inaishi, T; Kikumori, T; Maeda, O; Matsumoto, N; Nakayama, G; Shimokata, T,
)
0.55

Bioavailability

ExcerptReferenceRelevance
" Average bioavailability was assessed by ANOVA."( Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Baken, BC; Erlinghagen, V; Fuhr, U; Kubeš, V; Novotný, V; Peroutka, R; Queckenberg, C; Van Os, SH; Wargenau, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Fluoropyrimidine Pathway, Pharmacokinetics248
Fluoropyrimidine activity015

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1131068Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 12.5 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID1131065Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 100 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID1131064Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 200 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID1131066Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 50 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID1131067Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 25 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID55383Susceptibility to Cyd deaminase at a substrate concentration of 2.0 mM2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.33)18.7374
1990's0 (0.00)18.2507
2000's13 (43.33)29.6817
2010's14 (46.67)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.35 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.68 (4.65)
Search Engine Demand Index27.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (12.90%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]